A GHRH analogue approved for one defined HIV-related indication and investigated in studies of visceral fat and the GH/IGF-1 axis
Overview
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), the hypothalamic hormone that instructs the pituitary to release growth hormone. In contrast with most research peptides, Tesamorelin is the active substance of an FDA-approved medicine: EGRIFTA, first authorised in the United States in 2010 for reducing excess abdominal fat in adult HIV patients with lipodystrophy [1]. That regulatory context matters. Tesamorelin is not approved as a general weight-loss medicine, and its indication does not extend to "weight reduction" in people without HIV. The current FDA label states explicitly that it is not intended for weight management and that its long-term cardiovascular safety has not been established [1]. In research terms, Tesamorelin has a wider human evidence base than CJC-1295 or other investigational GH secretagogues, because phase 3 trials and clinical follow-up were carried out in the target population [2-5].
Biological Mechanism
Tesamorelin attaches to pituitary GHRH receptors and raises the body's own secretion of growth hormone. Higher GH in turn drives up IGF-1, a key mediator of a number of growth hormone's effects on metabolism, adipose tissue and other tissues [1,2]. This mechanism is distinct from administering GH directly: a GHRH analogue works through the pituitary and relies on the hypothalamic-pituitary axis being able to respond. Even so, endogenous stimulation is not automatically fully "physiological," since it involves a pharmacological exposure capable of lifting GH/IGF-1 axis activity above baseline. The effect on adipose tissue appears most marked in visceral fat. Studies in people with HIV and lipodystrophy reported a reduction in intra-abdominal fat, whereas the effect on subcutaneous fat differed and was at times smaller [2-4].
Research Evidence
A multicentre trial reported in the New England Journal of Medicine found that Tesamorelin reduced visceral fat in HIV patients with abdominal fat accumulation and improved certain blood lipid measures [2]. Further phase 3 trials, with follow-up lasting up to roughly one year, supported an average visceral fat reduction of approximately 15%-20% in the populations studied [3]. A randomised trial published in JAMA in 2014 also looked at hepatic fat and reported reductions in both visceral and liver fat versus placebo after six months, while the investigators stressed that more studies are needed to understand the long-term clinical significance [4]. A 2024 study in people with HIV on integrase inhibitor-based regimens again observed reductions in visceral and hepatic fat, with no significant worsening of glucose control relative to placebo in the group examined [5]. These data reinforce the metabolic effect within the target population but do not automatically extend the indication to the general population.
Visceral Fat Is Not the Same as Body Weight
A central point when interpreting Tesamorelin is the distinction between a shift in fat composition and a fall in total body weight. The approved treatment aims to reduce excess abdominal fat linked to lipodystrophy in HIV; it is not a general treatment for obesity [1]. Visceral fat lies within the abdominal cavity, surrounding the internal organs, and behaves differently in metabolic terms from subcutaneous fat, so it can decrease without any large change in overall weight. This is also why MRI/CT measures, or measurements of body circumference and composition, may carry more meaning in studies of this kind than a reading on the scales. Keeping this distinction in view guards against the misleading marketing of Tesamorelin as a "weight-loss peptide." The strongest evidence concerns one defined clinical population and one specific adipose-tissue measure.
Safety & Regulation
The FDA label for EGRIFTA WR includes warnings about raised IGF-1, fluid retention, joint pain, carpal tunnel-like symptoms, glucose intolerance or diabetes, and hypersensitivity reactions [1]. It also refers specifically to active or previous malignancies, given that the GH/IGF-1 pathway is involved in cell growth. The FDA notes that IGF-1 may increase during treatment and that the consequences of a sustained rise are not fully understood, and long-term cardiovascular safety has likewise not been established [1]. Because this is a medicine approved for a defined indication, the safety data for the approved product must be kept separate from those for unapproved products or compounded preparations. Approval of an active substance within one specific product does not make every product containing that substance equivalent in quality, stability or safety.
Approved Indication vs. Off-Label Uses
Tesamorelin neatly demonstrates the gap between "a molecule with metabolic activity" and "a medicine approved for any metabolic purpose." Its approval rests on a defined population, defined outcomes, manufacturing quality and a safety programme. It is not an approval for treating general obesity, for building muscle, for "anti-ageing," or for enhancing performance. In the same way, studies on hepatic fat do not amount to approval for treating fatty liver disease in any population. A clinical trial may show a positive signal on one particular measure, but broadening an indication requires its own development programme and a separate benefit-risk assessment.
Summary
Tesamorelin is a GHRH analogue backed by a comparatively substantial research and regulatory record. In the USA it is approved solely for reducing excess abdominal fat in adult HIV patients with lipodystrophy, not for general weight management [1]. Randomised studies have examined changes in fat composition [2-5], but stimulating the GH/IGF-1 axis carries metabolic risks and unresolved long-term safety questions that call for a medical framework. The material offered here is supplied for laboratory research use only.
Selected Research Sources
- U.S. Food and Drug Administration. EGRIFTA WR (tesamorelin) Prescribing Information. Revised 2025; initial U.S. approval 2010.
- Falutz J. et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007. PMID: 18057338
- Falutz J. et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: randomized placebo-controlled trial with safety extension. Journal of Acquired Immune Deficiency Syndromes, 2010. PMID: 20101189
- Stanley T.L. et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 2014. PMID: 25038357
- Russo S.C. et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS, 2024. PMID: 38905488
- Falutz J. et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled analysis of two multicenter phase 3 trials. Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20554713
